esuberaprost
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Esuberaprost (United Therapeutics) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor. PGI2 agonists are potent vasodilators and platelet aggregation inhibitors, and also help relax smooth muscle cells by counteracting the effect of vasoconstrictive mediators.
Analyst Outlook
United Therapeutics has ceded a large advantage in the time required to develop and formulate esuberaprost as an oral prostacyclin. The pulmonary hypertension (PH) market now contains both Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) and Orenitram (treprostinil; United Therapeutics) to occupy the oral prostacyclin niche, leaving esuberaprost a much narrower potential indication to be used as an adjunctive to inhaled Tyvaso (treprostinil; United Therapeutics/Mochida). This narrow therapeutic role, combined with questions surrounding esuberaprost’s efficacy, leaves the drug with restricted commercial potential
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 esuberaprost : Pulmonary hypertension
LIST OF FIGURES
10 Figure 1: Esuberaprost for pulmonary hypertension – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of esuberaprost for pulmonary hypertension
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of esuberaprost for pulmonary hypertension
14 Figure 4: Esuberaprost sales for pulmonary hypertension in the US, 2016–25
LIST OF TABLES
5 Table 1: Esuberaprost drug profile
7 Table 2: Esuberaprost Phase II data in pulmonary arterial hypertension
10 Table 3: Esuberaprost Phase III trials in pulmonary arterial hypertension
15 Table 4: Esuberaprost sales for pulmonary hypertension in the US ($m), 2016–25
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
ralinepag 
Sign up to the